Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Sep 18.

Published in final edited form as: Biomed Pharmacother. 2010 Nov 4;64(10):723–732. doi: 10.1016/j.biopha.2010.10.001

Table 1.

In vitro cytotoxicity and antiviral activities of PDBGs and control compounds.

Compound (linkers)	Cytotoxicity: CC₅₀ (%)			Antiviral activity: IC₅₀ (%)
Compound (linkers)	10-min exposure	2-h exposure^a	6-h exposure	VII-IIIB^b	VII-BaL^b	CFI-IIIB	CAI-IIIB
PEHMB (2-6)	1.0930	0.7738	0.6995	0.0099	0.0147	0.0795	0.0128
PPHMB (3-6)	0.4116	0.1995	0.2046	0.0028	0.2032	0.1646	0.0054
PBHMB (4-6)	0.4221	0.0707	0.0534	0.0023	0.0042	0.0749	0.0085
PEOMB (2-8)	0.1624	0.0657	0.0274	0.0011	0.0013	0.0300	0.0028
PHMB (6-6)	0.0461	0.0094	0.0088	ND	ND	ND	ND
PEDMB (2-10)	0.0301	0.0163	0.0131	ND	ND	ND	ND
PEDDMB (2-12)	0.0169	0.0080	0.0044	ND	ND	ND	ND
N-9	0.0645	0.0061	0.0056	ND	ND	ND	ND
DS	> 2	> 1	> 1	< 0.0001	0.0008	0.0034	0.0009
PEHMB (2-6)^c	ND	2.1	ND	0.0003	0.0079	ND	ND

DS: Dextran Sulfate; ND: not determined.

^a

CC₅₀ values were calculated from results illustrated in Fig. 2.

^b

IC₅₀ values were calculated from results illustrated in Fig. 3.

^c

PEHMB (2-6) (also known as NB325) produced using an improved synthesis protocol and partial purification.